ALIVUS LIFE SCIENCES LTD (ALIVUS) financials

ALIVUS LIFE SCIENCES LTD (ALIVUS) NSE/BSE financials on Fincrux: quarterly results, profit and loss, cash flow, balance sheet, ratios, and shareholding.

Glenmark Life Sciences, a subsidiary of Nirma Limited, a diversified conglomerate with interest in consumer products, cement, chemicals and pharmaceuticals. It is a leading developer and manufacturer of select, high-value, non-commoditized, active pharmaceutical ingredients (APIs) in chronic therapeutic areas. The company further operates in Contract Development and manufacturing operations to of…

Market Cap: ₹16,077Cr.
Current Price: ₹1,310
Stock P/E: 25.9
ROE: 17.9%
ROCE: 23.8%
Book Value: ₹271
Dividend Yield: 0.38%
52W High / Low: ₹1,495/819

In Jun 2026, ALIVUS LIFE SCIENCES LTD (ALIVUS) reported sales ₹640 Cr and net profit ₹160 Cr.

Annual TTM: sales ₹2,590 Cr, net profit ₹603 Cr.

Shareholding: Promoters 74.85% (Sep 2026), FIIs 5.93% (Sep 2026), DIIs 7.03% (Sep 2026), Public 12.19% (Sep 2026), No. of Shareholders 1,22,777% (Sep 2026).

ALIVUS quarterly results (₹ Cr.)
Category	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Sales	507	642	650	602	588	673	689	640
Expenses	373	452	451	430	409	442	475	429
Operating Profit	134	190	198	172	179	231	215	212
OPM %	27%	30%	31%	29%	30%	34%	31%	33%
Other Income	9	10	10	9	15	-12	23	22
Interest	0	0	1	1	1	1	1	1
Depreciation	15	15	16	17	18	20	20	21
Profit before tax	127	185	191	163	174	198	216	212
Tax %	25%	26%	26%	25%	25%	24%	25%	25%
Net Profit	95	137	142	122	130	150	163	160
EPS in Rs	7.78	11.18	11.58	9.91	10.60	12.25	13.25	13.04
Raw PDF	—	—	—	—	—	—	—	—

ALIVUS profit and loss (₹ Cr.)
Category	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
Sales	1,537	1,885	2,123	2,161	2,283	2,387	2,552	2,590
Expenses	1,064	1,294	1,506	1,518	1,608	1,702	1,754	1,754
Operating Profit	473	592	617	643	675	684	798	837
OPM %	31%	31%	29%	30%	30%	29%	31%	32%
Other Income	11	0	14	28	11	33	34	48
Interest	34	88	28	1	2	2	5	5
Depreciation	29	33	38	42	53	61	75	79
Profit before tax	421	471	565	629	631	654	751	801
Tax %	26%	25%	26%	26%	25%	26%	25%	—
Net Profit	313	352	419	467	471	486	564	603
EPS in Rs	29.04	32.61	34.17	38.11	38.43	39.63	45.99	49.14
Dividend Payout %	0%	0%	61%	110%	59%	13%	11%	—

ALIVUS balance sheet (₹ Cr.)
Category	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	2	2	2	25	25	25	25	25
Reserves	86	400	751	2,030	2,114	2,308	2,793	3,308
Borrowings	0	0	0	3	19	17	57	57
Other Liabilities	1,387	1,324	1,244	414	545	501	537	594
Total Liabilities	1,475	1,726	1,997	2,471	2,702	2,850	3,411	3,983
Fixed Assets	456	546	573	595	781	805	955	1,038
CWIP	80	11	14	92	62	106	102	284
Investments	0	0	0	0	0	0	478	780
Other Assets	939	1,169	1,410	1,784	1,860	1,939	1,877	1,881
Total Assets	1,475	1,726	1,997	2,471	2,702	2,850	3,411	3,983

ALIVUS cash flows (₹ Cr.)
Category	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Cash from Operating Activity	10	195	388	598	306	414	392	565
Cash from Investing Activity	-9	-51	-69	-122	-147	-116	-616	-570
Cash from Financing Activity	1	-137	-214	-79	-388	-279	-6	-64
Net Cash Flow	2	8	106	397	-228	18	-230	-69
Free Cash Flow	1	144	322	466	143	285	226	259
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit	14%	61%	84%	119%	71%	85%	81%	93%

ALIVUS shareholding pattern (%)
Category	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026	Sep 2026
Promoters	75.00%	74.99%	74.94%	74.91%	74.91%	74.87%	74.87%	74.85%
FIIs	6.74%	6.57%	6.42%	6.84%	5.08%	5.30%	5.54%	5.93%
DIIs	4.86%	5.19%	5.62%	5.47%	7.13%	7.27%	7.18%	7.03%
Public	13.40%	13.25%	13.03%	12.79%	12.89%	12.55%	12.42%	12.19%
No. of Shareholders	1,46,840	1,41,977	1,38,500	1,35,643	1,32,748	1,27,969	1,25,559	1,22,777

ALIVUS key ratios
Category	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor Days	185	152	120	116	136	122	148	153
Inventory Days	441	227	214	185	224	251	237	246
Days Payable	201	111	92	110	158	139	137	132
Cash Conversion Cycle	424	268	241	190	202	235	248	267
Working Capital Days	-186	-37	12	149	176	188	201	194
ROCE %	529%	186%	97%	42%	30%	28%	25%	24%

ALIVUSUpdated 19 Oct 2026, 5:04

Alivus Life Sciences Ltd

ALIVUSUpdated 19 Oct 2026, 5:04

Market Cap

₹16,077Cr.

Current Price

₹1,310

High / Low

₹1,495/819

Stock P/E

25.9

ROE17.9%

ROCE23.8%

Book Value₹271

Face Value₹2.00

Dividend Yield0.38%

About

Quarterly results

Last reported quarters₹ Cr.

Quarter	Sales	Interest	Expenses	Other Income	Depreciation	Profit Before Tax	Tax	Net Profit	EPS (₹)
Jun 2023	578	0	385	2	13	182	26	135	11.05
Sep 2023	595	0	428	5	13	159	25	119	9.69
Dec 2023	573	0	400	2	13	161	26	119	9.69
Mar 2024	537	0	395	3	15	130	24	98	7.99
Jun 2024	589	0	429	5	14	150	26	111	9.1
Sep 2024	507	0	373	9	15	127	25	95	7.78
Dec 2024	642	0	452	10	15	185	26	137	11.18
Mar 2025	650	1	451	10	16	191	26	142	11.58
Jun 2025	602	1	430	9	17	163	25	122	9.91
Sep 2025	588	1	409	15	18	174	25	130	10.6
Dec 2025	673	1	442	-12	20	198	24	150	12.25
Mar 2026	689	1	475	23	20	216	25	163	13.25
Jun 2026	640	1	429	22	21	212	25	160	13.04

Profit & loss

Annual statement₹ Cr.

Year	Sales	Interest	Expenses	Other Income	Depreciation	Profit Before Tax	Tax	Net Profit	EPS (₹)
Mar 2018	0	0	0	0	0	0	4200	0	-3.91
Mar 2019	886	1	638	0	19	228	14	196	18.14
Mar 2020	1537	34	1064	11	29	421	26	313	29.04
Mar 2021	1885	88	1294	0	33	471	25	352	32.61
Mar 2022	2123	28	1506	14	38	565	26	419	34.17
Mar 2023	2161	1	1518	28	42	629	26	467	38.11
Mar 2024	2283	2	1608	11	53	631	25	471	38.43
Mar 2025	2387	2	1702	33	61	654	26	486	39.63
Mar 2026	2552	5	1754	34	75	751	25	564	45.99
TTM	2590	5	1754	48	79	801	—	603	49.14

Shareholding pattern

As of Sep 2026%

Holder	Share
Promoters	74.85%
FIIs	5.93%
DIIs	7.03%
Public	12.19%

Shareholding trend

Ownership over time%

Quarter	Promoters	FIIs	DIIs	Public
Dec 2023	82.85%	4.57%	0.74%	11.84%
Mar 2024	82.85%	5.01%	1.41%	10.73%
Jun 2024	82.85%	4.81%	1.57%	10.76%
Sep 2024	75%	7.85%	4.16%	12.99%
Dec 2024	75%	6.74%	4.86%	13.4%
Mar 2025	74.99%	6.57%	5.19%	13.25%
Jun 2025	74.94%	6.42%	5.62%	13.03%
Sep 2025	74.91%	6.84%	5.47%	12.79%
Dec 2025	74.91%	5.08%	7.13%	12.89%
Mar 2026	74.87%	5.3%	7.27%	12.55%
Jun 2026	74.87%	5.54%	7.18%	12.42%
Sep 2026	74.85%	5.93%	7.03%	12.19%

Balance sheet

Assets & liabilities₹ Cr.

Period	Equity Capital	Reserves	Borrowings	Other Liabilities	Total Liabilities	Fixed Assets	CWIP	Investments	Other Assets	Total Assets
Mar 2018	0.01	-1	0	1	0	0	0	0	0	0
Mar 2019	2	86	0	1387	1475	456	80	0	939	1475
Mar 2020	2	400	0	1324	1726	546	11	0	1169	1726
Mar 2021	2	751	0	1244	1997	573	14	0	1410	1997
Mar 2022	25	2030	3	414	2471	595	92	0	1784	2471
Mar 2023	25	2114	19	545	2702	781	62	0	1860	2702
Mar 2024	25	2308	17	501	2850	805	106	0	1939	2850
Mar 2025	25	2793	57	537	3411	955	102	478	1877	3411
Mar 2026	25	3308	57	594	3983	1038	284	780	1881	3983

Cash flows

Operating, investing & financing₹ Cr.

Period	Operating	Investing	Financing	Net cash flow
Mar 2018	0	0	0	0
Mar 2019	10	-9	1	2
Mar 2020	195	-51	-137	8
Mar 2021	388	-69	-214	106
Mar 2022	598	-122	-79	397
Mar 2023	306	-147	-388	-228
Mar 2024	414	-116	-279	18
Mar 2025	392	-616	-6	-230
Mar 2026	565	-570	-64	-69

Key ratios

Historical financial ratios

Category	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor Days	44	185	152	120	116	136	122	148	153
Inventory Days	162	441	227	214	185	224	251	237	246
Days Payable	41	201	111	92	110	158	139	137	132
Cash Conversion Cycle	165	424	268	241	190	202	235	248	267
Working Capital Days	-2,059	-186	-37	12	149	176	188	201	194
ROCE %	—	529%	186%	97%	42%	30%	28%	25%	24%

Frequently asked questions

Quick answers about this company's financials on Fincrux

What is the market cap of ALIVUS LIFE SCIENCES LTD (ALIVUS)?

The reported market capitalisation for ALIVUS LIFE SCIENCES LTD (ALIVUS) is ₹16,077Cr. on Fincrux. Figures may update with market data and filings.

What is the current share price of ALIVUS?

The current price shown for ALIVUS LIFE SCIENCES LTD (ALIVUS) on Fincrux is ₹1,310 with a 52-week high/low of ₹1,495/819.

What is the P/E ratio of ALIVUS LIFE SCIENCES LTD (ALIVUS)?

The stock P/E for ALIVUS LIFE SCIENCES LTD (ALIVUS) is 25.9 on Fincrux, with ROE at 17.9% and ROCE at 23.8%.

What were ALIVUS latest quarterly results?

For Jun 2026, ALIVUS LIFE SCIENCES LTD (ALIVUS) reported sales ₹640 Cr and net profit ₹160 Cr (figures in ₹ crore unless noted).

What are ALIVUS annual sales and net profit?

For TTM, ALIVUS LIFE SCIENCES LTD (ALIVUS) shows sales of ₹2,590 Cr and net profit of ₹603 Cr on the Fincrux profit & loss statement.

Who owns ALIVUS LIFE SCIENCES LTD (ALIVUS)?

Latest shareholding for ALIVUS LIFE SCIENCES LTD (ALIVUS) on Fincrux: Promoters 74.85% (Sep 2026), FIIs 5.93% (Sep 2026), DIIs 7.03% (Sep 2026), Public 12.19% (Sep 2026), No. of Shareholders 1,22,777% (Sep 2026).

Where can I find ALIVUS LIFE SCIENCES LTD (ALIVUS) financials?

ALIVUS LIFE SCIENCES LTD (ALIVUS) financials on Fincrux include quarterly results, profit and loss, cash flow, balance sheet, key ratios, and shareholding patterns for NSE/BSE research.

Does Fincrux show ALIVUS balance sheet and cash flow?

Yes. The ALIVUS LIFE SCIENCES LTD (ALIVUS) page on Fincrux includes balance sheet, cash flow statements, historical ratios, and ownership trends alongside quarterly and annual results.

Figures in ₹ crore unless noted. Data sourced for research and may lag filings.

Last updated 19 October 2026 at 5:04